OptiBiotix Health (LSE:OPTI) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


What is OptiBiotix Health Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

OptiBiotix Health's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LSE:OPTI vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, OptiBiotix Health's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptiBiotix Health Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OptiBiotix Health's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where OptiBiotix Health's Margin of Safety % (DCF Earnings Based) falls into.


OptiBiotix Health Business Description

Address Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.